参与物
| 角色 | 名称 | HCID | 投料 |
|---|
| 反应物 | 4-苄氧基溴苯 | HCID 138835 | — |
| 反应物 | (R)-4-Boc-2-甲基哌嗪 | HCID 2756811 | — |
| 试剂 | 叔丁醇钾 | HCID 23665647 | — |
| 催化剂 | 三叔丁基膦 | HCID 83681 | — |
| 催化剂 | 二(三叔丁基膦)钯 | HCID 2734558 | — |
| 溶剂 | 四氢呋喃 | HCID 8028 | — |
| 产物 | (R)-4-(4-benzyloxyphenyl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester | HCID 70873375 | 31.55% |
反应步骤
A mixture of 1-(benzyloxy)-4-bromobenzene (789 mg, 3.00 mmol), (R)-tert-butyl 3-methylpiperazine-1-carboxylate (300 mg, 1.5 mmol), bis(tri-t- butylphosphine)palladium(0) (77 mg, 0.15 mmol) and potassium tert-butoxide (185 mg, 1.65 mmol) in THF (10 mL) was flushed with nitrogen and heated to 75 °C overnight. A further 0.1eq of bis(tri-t-butylphosphine)palladium(0) (77 mg, 0.15 mmol) was added and the reaction was heated for a further 2.5 hours. The solvent was evaporated and the residue dissolved in MeOH (10mL) and purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 0.35M NH3/MeOH and purified further by flash silica chromatography, elution gradient 0 to 20% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford (R)-tert-butyl 4-(4-(benzyloxy)phenyl)-3-methylpiperazine-1-carboxylate (181 mg, 31.5 %) as an orange oil.
来源与证据
| 来源数据集 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-53993d3e76914a9480a25e3f9305c2e9 |
|---|
| 来源说明 | 750 AstraZeneca ELN dataset |
|---|